Dnanexus, Inc.
Mountain View, CA
- UEI
- D3WLJYBFS2M3
- CAGE
- 5KNP1
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1975 W El Camino Real #204, Mountain View, CA 94040, USA
- Website
- dnanexus.com
- Founded
- 2009
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Information Technology
- Software & Services
- IT Services
- Data Processing & Outsourced Services
- SIC code
- 73 Business Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $2,568,620 |
| FY2025 | $10,827,310 |
| FY2024 | $5,397,128 |
| FY2023 | $5,085,468 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $2,568,620 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Human variation detection and visualization on the dnanexus web 2.0 platform | National Institutes of Health | $74,477 |
Similar vendors
About the company
Dnanexus, Inc., based in Mountain View, California, delivers cloud-based genomics data management, bioinformatics analysis, and precision medicine research infrastructure to federal health agencies as a prime contractor on 100% of its recent awards, competing predominantly in full-and-open (non-set-aside) procurements with occasional small-business set-aside delivery orders from the FDA.
Dnanexus operates as a for-profit corporate entity with a specialized capability portfolio anchored in FISMA-authorized secure cloud platforms for genomic research and regulatory science collaboration. The company's core offering centers on the PrecisionFDA platform—a collaborative genomics and omics environment supporting FDA researchers, reviewers, and bioinformaticians—alongside the Research Analysis Platform (RAP) for large-scale deidentified dataset analysis and the ADAPT Treatment and Analysis Platform (TAP) for precision cancer therapy analytics. Representative recent work includes a $15 million Other Transaction Agreement from the National Institutes of Health (awarded May 20, 2025, running through May 19, 2031) for development and delivery of the ADAPT platform for advanced cancer therapy analysis; a $2.17 million delivery order from the FDA (September 30, 2026) for the PrecisionFDA High Platform under full-and-open competition; and a $647.5 thousand purchase order from the National Cancer Institute (September 9, 2024) for Platform as a Service cloud-based data analysis capabilities supporting the Confluence Project. The company also holds a $1.05 million definitive contract from the FDA (September 9, 2024) for development of the PRISM platform pilot supporting pre-submission validation of eCTDs.
Customer concentration sits entirely within the Department of Health and Human Services. The FDA accounts for 20 awards and $68 million (81% of combined potential value), with a long-running $20 million indefinite delivery contract serving as the parent vehicle for 15 of those task orders valued at $26.6 million combined. The National Institutes of Health and its component institutes—the National Cancer Institute, the National Human Genome Research Institute, the National Institute on Aging, and the National Institute on Heart, Lung, and Blood—collectively represent 9 awards valued at approximately $15.9 million. These six distinct customer agencies span 32 total prime awards covering 97% of the portfolio by award count.
Activity has declined markedly in recent years. Dnanexus received six awards in 2022, three in 2023, five in 2024, three in 2025, and two in 2026 year-to-date. Only three awards (combined potential value $3.1 million) reach ultimate completion in the next twenty-four months, creating limited near-term recompete exposure. Combined potential value across all 32 awards stands at $84 million, with $42.7 million obligated to date (51% of potential).
Service Contract Inventory data shows SCI-reportable invoiced revenue of $3.6 million in FY2022, $4.8 million in FY2023, $1.1 million in FY2024, and $421 thousand in FY2025 across a declining federal services workforce: 7.0 FTEs in FY2022 contracting down to 1.1 FTEs in FY2025. On SCI-reportable prime contracts, Dnanexus self-performs 99% of reported hours, with minimal subcontractor engagement (1% average sub-hours share and only one named subcontractor across the SCI-reportable prime contract footprint). Government-paid hourly rates on federal services work run a median of approximately $311.49 per hour, with senior labor pricing through $570.23 per hour at the 90th percentile.
Quick answers
Is Dnanexus, Inc. registered in SAM.gov?
Yes. Dnanexus, Inc.'s SAM.gov registration is active through August 30, 2027.
How much has Dnanexus, Inc. received in federal contracts?
Federal contracts obligated $10,827,310 to Dnanexus, Inc. in fiscal year 2025 and $23,878,525 in fiscal years 2023 through 2027.
How does Dnanexus, Inc. rank among federal contractors?
Dnanexus, Inc. ranked #42 in PSC AN13 and #81 in PSC 7A20 in FY2025.
What is Dnanexus, Inc.'s most recent federal award?
Dnanexus, Inc.'s most recent federal contract award is Precisionfda high platform (75F40126F19001), from Food and Drug Administration, on September 30, 2026.
On GovTribe
See Dnanexus, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors